3D bioprinting company Organovo Holdings presented another breakthrough at the 2015 Experimental Biology conference in Boston.
For the first time researchers 3D printed in vitro kidney tissue, using the company’s proprietary NovoGen bioprinting platform. The human kidney proximal tubular tissues consists of multiple tissue-relevant cell types arranged to recapitulate the renal tubular.
Keith Murphy, Chairman and CEO at Organovo explains:
“Kidney represents an ideal extension of Organovo’s capabilities to 3D bioprint organ tissues that can be tremendously useful in pharmaceutical research. The results released today admirably demonstrate a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo. The product that we intend to build from these initial results can be an excellent expansion for our core customers in toxicology, who regularly express to us an interest in having better solutions for the assessment of human kidney toxicity.”
Back in November last year Organovo announced the commercial release of their 3D bioprinted, human liver tissue called exVive3D. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems.